Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000198141 | SCV000254450 | likely benign | Gorlin syndrome | 2024-08-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003165466 | SCV003912825 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-02-24 | criteria provided, single submitter | clinical testing | The p.F376L variant (also known as c.1128C>G), located in coding exon 8 of the PTCH1 gene, results from a C to G substitution at nucleotide position 1128. The phenylalanine at codon 376 is replaced by leucine, an amino acid with highly similar properties. This alteration has been reported as a variant of unknown significance in an individual with early onset breast cancer from a cohort of 1191 cancer index patients who underwent clinical evaluation and testing with multigene panels (Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV004567433 | SCV005052497 | uncertain significance | Basal cell carcinoma, susceptibility to, 1 | 2024-03-14 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005042424 | SCV005679700 | uncertain significance | Basal cell carcinoma, susceptibility to, 1; Holoprosencephaly 7; Basal cell nevus syndrome 1 | 2024-01-03 | criteria provided, single submitter | clinical testing |